IL162776A0 - 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence - Google Patents

2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence

Info

Publication number
IL162776A0
IL162776A0 IL16277602A IL16277602A IL162776A0 IL 162776 A0 IL162776 A0 IL 162776A0 IL 16277602 A IL16277602 A IL 16277602A IL 16277602 A IL16277602 A IL 16277602A IL 162776 A0 IL162776 A0 IL 162776A0
Authority
IL
Israel
Prior art keywords
dialkoxyphen
imino
halo
treatment
urinary incontinence
Prior art date
Application number
IL16277602A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of IL162776A0 publication Critical patent/IL162776A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16277602A 2002-01-31 2002-12-16 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence IL162776A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02002352A EP1333028A1 (en) 2002-01-31 2002-01-31 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
PCT/EP2002/014299 WO2003064398A1 (en) 2002-01-31 2002-12-16 2'-halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence

Publications (1)

Publication Number Publication Date
IL162776A0 true IL162776A0 (en) 2005-11-20

Family

ID=8185397

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16277602A IL162776A0 (en) 2002-01-31 2002-12-16 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence

Country Status (20)

Country Link
EP (2) EP1333028A1 (enExample)
JP (1) JP2005516066A (enExample)
KR (1) KR20040074134A (enExample)
CN (1) CN1617857A (enExample)
AR (1) AR038380A1 (enExample)
BR (1) BR0215560A (enExample)
CA (1) CA2474588A1 (enExample)
EA (1) EA200400877A1 (enExample)
EC (1) ECSP045210A (enExample)
HR (1) HRP20040691A2 (enExample)
HU (1) HUP0402654A2 (enExample)
IL (1) IL162776A0 (enExample)
MX (1) MXPA04007250A (enExample)
NO (1) NO20043614L (enExample)
PE (1) PE20030819A1 (enExample)
PL (1) PL369826A1 (enExample)
TW (1) TW200418462A (enExample)
UY (1) UY27628A1 (enExample)
WO (1) WO2003064398A1 (enExample)
ZA (1) ZA200405173B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4168086B1 (ja) * 2008-04-16 2008-10-22 国立大学法人福井大学 イミダゾリン誘導体
AU2009246601A1 (en) * 2008-05-13 2009-11-19 Allergan, Inc. Quinolynylmethylimidizoles as therapeutic agents
WO2009140137A1 (en) * 2008-05-13 2009-11-19 Allergan, Inc. Naphthylmethylimidizoles for the treatment of stress urinary incontinence
US8063231B2 (en) * 2008-06-09 2011-11-22 Allergan, Inc. Methods of treating alpha adrenergic mediated conditions
US8071636B2 (en) * 2008-06-09 2011-12-06 Allergan, Inc. Methods of treating alpha adrenergic mediated conditions
US9034910B2 (en) 2008-06-09 2015-05-19 Allergan, Inc. Methods of treating alpha adrenergic mediated conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2220906A1 (de) * 1972-04-28 1973-11-15 Boehringer Sohn Ingelheim Neue substituierte 2-phenylaminoimidazoline-(2), deren saeureadditionssalze sowie verfahren zu deren herstellung
DE2259160A1 (de) * 1972-12-02 1974-06-06 Boehringer Sohn Ingelheim Neue substituierte 2-phenylaminoimidazoline, deren saeureadditionssalze und verfahren zur herstellung derselben sowie ihre verwendung als arzneimittel
AT333749B (de) * 1974-07-03 1976-12-10 Chemie Linz Ag Verfahren zur herstellung von neuen 2-arylamino-2-imidazolinderivaten
MTP837B (en) * 1977-11-07 1979-10-22 Hoffman La Roche And Co Aktien Derivatives 2 finino-imidazolidire
DE3514351A1 (de) * 1985-04-20 1986-11-06 Boehringer Ingelheim KG, 6507 Ingelheim Neue substituierte 2-(n-alkinyl-n-phenyl)amino)-imidazolinderivate, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu deren herstellung
DE19514579A1 (de) * 1995-04-20 1996-10-24 Boehringer Ingelheim Kg Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
SG72827A1 (en) * 1997-06-23 2000-05-23 Hoffmann La Roche Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
DE19740176C2 (de) * 1997-09-12 2000-04-06 Lemfoerder Metallwaren Ag Handschaltvorrichtung für ein Kraftfahrzeug

Also Published As

Publication number Publication date
TW200418462A (en) 2004-10-01
PE20030819A1 (es) 2003-10-20
CN1617857A (zh) 2005-05-18
EA200400877A1 (ru) 2005-02-24
HRP20040691A2 (en) 2004-12-31
CA2474588A1 (en) 2003-08-07
WO2003064398A1 (en) 2003-08-07
NO20043614L (no) 2004-08-30
ECSP045210A (es) 2004-09-28
EP1333028A1 (en) 2003-08-06
BR0215560A (pt) 2004-12-21
MXPA04007250A (es) 2004-10-29
EP1472231A1 (en) 2004-11-03
UY27628A1 (es) 2003-08-29
PL369826A1 (en) 2005-05-02
ZA200405173B (en) 2005-06-21
JP2005516066A (ja) 2005-06-02
AR038380A1 (es) 2005-01-12
KR20040074134A (ko) 2004-08-21
HUP0402654A2 (hu) 2005-03-29

Similar Documents

Publication Publication Date Title
AU2001275257A1 (en) Methods and devices for the treatment of urinary incontinence
IL173439A0 (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
PL369763A1 (en) Heterocyclic compounds for use in the treatment of disorders of the urinary tract
PL366636A1 (en) Pyranoindazoles and their use for the treatment of glaucoma
PL372395A1 (en) Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
ZA200307731B (en) Use of selective COX-2inhibitors for the treatment of urinary incontinence.
NZ513650A (en) Pharmaceutical composition for the treatment of urinary incontinence, motion sickness and vertigo
AU2003214273A8 (en) Improved system for the treatment of stress urinary incontinence
HUP0200738A3 (en) Method of the treatment of incontinence
AUPQ968700A0 (en) Treatment of urinary incontinence
PL375564A1 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
EP1455780A4 (en) NEW BENZODIFURANIMIDAZOLIN AND BENZOFURANIMIDAZOLIN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA
IL162776A0 (en) 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
AU2003237657A1 (en) Means and methods for improved treatment using "setrones"
AU2003286068A1 (en) Process for the treatment of pig manure and the use thereof
AU2002315485A1 (en) Compositions and methods for the treatment of body weight disorders, including obesity
NO20012569D0 (no) Anvendelse av aryl-substituerte syklobutylaminer for behandling av urininkontinens
AU2003283153A8 (en) Pharmaceutical compositions for the treatment of urinary incontinence
EE200300379A (et) Alküülfenüüliminoimidasolidiini derivaadid uriinipidamatuse ravimiseks
AU2003249364A8 (en) Algal gdp-mannose-3',5'-epimerases and methods of use thereof
AU6686700A (en) Treatment of urinary incontinence
HUP0302245A3 (en) Novel m-amino-phenylimino-imidazolidine derivatives, their use and pharmaceutical compositions for treating urinary incontinence
NO20033428L (no) Anvendelse av 2-amino-1(4-hydroksy-3-metansulfonamidofenyl)- etanol for behandling av urin-inkontinens
AU2002253007A1 (en) Instrumentation for the operative treatment of urinary incontinence in women